Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis - Takeaways - MDSpire

Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis

  • By

  • Sy, Jann Adriel

  • Quah, Thuan Chong

  • Tee, Pian Pian

  • Ho, Cindy Wei Li

  • April 15, 2026

  • 0 min

Share

  • 1

    Intravenous zoledronate was evaluated in eight children with bone-associated LCH at National University Hospital, Singapore.

  • 2

    All four symptomatic patients treated with zoledronate experienced pain improvement, with a median time to improvement of 18 days.

  • 3

    Radiologic outcomes showed that 2 of 8 patients had complete resolution of lesions, while 6 demonstrated improvement.

  • 4

    The treatment was well tolerated, with transient fever reported in 4 patients but no significant hypocalcemia or osteonecrosis.

  • 5

    Zoledronate was used for painful bone lesions and as a chemotherapy-sparing approach in selected patients with LCH.

Original Source(s)

Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis

  • by Sy, Jann Adriel , Quah, Thuan Chong , Tee, Pian Pian , Ho, Cindy Wei Li

  • April 15, 2026

Related Content

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report